Drug Profile
Aderamastat - Foresee Pharmaceuticals
Alternative Names: FP-003; FP-025Latest Information Update: 11 Oct 2023
Price :
$50
*
At a glance
- Originator Foresee Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Small molecules
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III SARS-CoV-2 acute respiratory disease
- Phase II Allergic asthma
- Phase I Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 11 Oct 2023 Aderamastat is still in phase-I trials for Chronic obstructive pulmonary disorder (In volunteers) in Netherlands (Foresee Pharmaceutical pipeline; October 2023)
- 10 Oct 2023 Aderamastat is still in Phase-I clinical trials for Asthma (In volunteers) in Taiwan (PO) (NCT02238834) (Foresee Pharmaceuticals pipeline; October 2023)
- 10 Oct 2023 Aderamastat is still in phase-I trial for Chronic obstructive pulmonary disease (In volunteers) in Taiwan (PO) (NCT02238834) (Foresee Pharmaceuticals pipeline; October 2023)